40 research outputs found
PROFIL WISATAWAN MUSEUM RADYA PUSTAKA SURAKARTA
Anggit Margaret, C9407031 2011. Profil Wisatawan Museum
Radya Pustaka Surakarta. Program Studi Diploma III Usaha Perjalanan
Wisata Fakultas Sastra Dan Seni Rupa Universitas Sebelas Maret Surakarta.
Penelitian tugas akhir ini mengkaji tentang Profil Wisatawan di
Museum Radya Pustaka Surakarta. Tujuan dari penelitian ini adalah untuk
mengetahui dari daerah mana saja wisatawan yang berkunjung ke Museum
Radya Pustaka, bagaimana ciri-ciri wisatawan yang berkunjung ke Museum
Radya Pustaka serta harapan-harapan yang diinginkan wisatawan terhadap
Museum Radya Pustaka.
Penelitian dilakukan dengan metode kualitatif. Pengumpulan data
dilakukan melalui wawancara dengan narasumber wisatawan yang berkujung
di Museum Radya Pustaka Surakarta tempat penulis melakukan penelitian,
serta studi pustaka dan studi dokumen guna menambah sumber data.
Hasil penelitian menunjukkan bahwa (1) Sebagian besar wisatawan
yang datang berasal dari Semarang sebesar 32%. (2) Mayoritas wisatawan
yang berkunjung ke Museum Radya Pustaka berusia antara 17-25 tahun dan
kebanyakan dari mereka adalah pelajar atau mahasiswa dengan prosentase
52%. (3) Sebagian besar wisatawan yang datang ke Museum Radya Pustaka
adalah bertujuan untuk melakukan penelitian yaitu sebesar 34%. (4) Harapan
wisatawan yang berkunjung terhadap kelangsungan Museum Radya Pustaka
sebagian besar adalah agar ditingkatkan lagi pengelolaan dan keamanan
museum, agar kejadian hilangnya benda-benda koleksi museum tidak terulang
lagi dikemudian hari.
Kesimpulan dari hasil penelitian ini bahwa wisatawan yang berkujung
ke Museum Radya Pustaka Surakarta mayoritas berasal dari Semarang,
mayoritas berusia 17-25 tahun dan kebanyakan dari mereka adalah berprofesi
sebagai pelajar dan mahasiswa. Kebanyakan wisatawan yang datang bertujuan
untuk melakukan penelitian, serta harapan wisatawan terhadap Museum
Radya Pustaka adalah supaya lebih ditingkatkan lagi pengelolaan dan
keamanan museum
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
Background
Individuals with rare kidney diseases account for 5–10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.
Methods
People aged 0–96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan–Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window).
Findings
Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9–16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0·0001), but better survival rates (standardised mortality ratio 0·42 [95% CI 0·32–0·52]; p<0·0001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases.
Interpretation
Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3–5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand.
Funding
RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity
Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses
To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely
Whole-genome sequencing reveals host factors underlying critical COVID-19
Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease
Prematuration with Cyclic Adenosine Monophosphate Modulators Alters Cumulus Cell and Oocyte Metabolism and Enhances Developmental Competence of In Vitro-Matured Mouse Oocytes1
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal degenerative motor neuron disorder. Ten percent of cases are inherited; most involve unidentified genes. We report here 13 mutations in the fused in sarcoma/translated in liposarcoma (FUS/TLS) gene on chromosome 16 that were specific for familial ALS. The FUS/TLS protein binds to RNA, functions in diverse processes, and is normally located predominantly in the nucleus. In contrast, the mutant forms of FUS/TLS accumulated in the cytoplasm of neurons, a pathology that is similar to that of the gene TAR DNA-binding protein 43 (TDP43), whose mutations also cause ALS. Neuronal cytoplasmic protein aggregation and defective RNA metabolism thus appear to be common pathogenic mechanisms involved in ALS and possibly in other neurodegenerative disorders